Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
14.34
-0.03 (-0.21%)
At close: May 1, 2026, 4:00 PM EDT
14.15
-0.19 (-1.32%)
After-hours: May 1, 2026, 7:53 PM EDT
Janux Therapeutics Employees
Janux Therapeutics had 109 employees as of December 31, 2025. The number of employees increased by 28 or 34.57% compared to the previous year.
Employees
109
Change
28
Growth
34.57%
Revenue / Employee
$91,743
Profits / Employee
-$1,042,431
Market Cap
872.33M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 109 | 28 | 34.57% |
| Sep 30, 2025 | 109 | 33 | 43.42% |
| Jun 30, 2025 | 103 | 34 | 49.28% |
| Mar 31, 2025 | 91 | 23 | 33.82% |
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Sep 30, 2024 | 76 | 12 | 18.75% |
| Jun 30, 2024 | 69 | 2 | 2.99% |
| Mar 31, 2024 | 68 | 6 | 9.68% |
| Dec 31, 2023 | 64 | 4 | 6.67% |
| Sep 30, 2023 | 64 | 8 | 14.29% |
| Jun 30, 2023 | 67 | 18 | 36.73% |
| Mar 31, 2023 | 62 | 21 | 51.22% |
| Dec 31, 2022 | 60 | 27 | 81.82% |
| Sep 30, 2022 | 56 | 28 | 100.00% |
| Jun 30, 2022 | 49 | 27 | 122.73% |
| Mar 31, 2022 | 41 | 25 | 156.25% |
| Dec 31, 2021 | 33 | 21 | 175.00% |
| Sep 30, 2021 | 28 | 16 | 133.33% |
| Jun 30, 2021 | 22 | - | - |
| Mar 31, 2021 | 16 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| MeiraGTx Holdings | 403 |
| ARS Pharmaceuticals | 163 |
| Sana Biotechnology | 142 |
| Theravance Biopharma | 90 |
| Alto Neuroscience | 68 |
| Bright Minds Biosciences | 26 |
| Arbutus Biopharma | 19 |
JANX News
- 6 days ago - Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development - Business Wire
- 17 days ago - Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 - Business Wire
- 4 weeks ago - Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Business Wire
- 2 months ago - Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
- 2 months ago - Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 - Business Wire
- 3 months ago - Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire
- 3 months ago - Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
- 3 months ago - Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters